[1]卢美红,杨曙梅,王　峰,等.血清miRNA-574-3p,AFP，IGF-2水平联合检测在肝癌早期诊断中的价值研究[J].现代检验医学杂志,2022,37(02):33-36.[doi:10.3969/j.issn.1671-7414.2022.02.007]
　LU Mei-hong,YANG Shu-mei,WANG Feng,et al.Study on the Value of Combined Detection of Serum miRNA-574-3p,AFP and IGF-2 Levels in the Early Diagnosis of Liver Cancer[J].Journal of Modern Laboratory Medicine,2022,37(02):33-36.[doi:10.3969/j.issn.1671-7414.2022.02.007]
点击复制

血清miRNA-574-3p,AFP，IGF-2水平联合检测在肝癌早期诊断中的价值研究()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第37卷
期数:
2022年02期
页码:
33-36
栏目:
论　著
出版日期:
2022-03-15

文章信息/Info

Title:
Study on the Value of Combined Detection of Serum miRNA-574-3p,AFP and IGF-2 Levels in the Early Diagnosis of Liver Cancer
文章编号:
1671-7414（2022）02-033-04
作者:
卢美红; 杨曙梅; 王　峰; 王旭东; 鞠少卿
（南通大学附属医院医学检验科，江苏南通 226001）
Author(s):
LU Mei-hong ; YANG Shu-mei ; WANG Feng ; WANG Xu-dong ; JU Shao-qing
（Department of Laboratory Medicine, Affiliated Hospital of Nantong University, Jiangsu Nantong 226001,China ）
关键词:
早期肝癌; miRNA-574-3p; 甲胎蛋白; 胰岛素样生长因子-2; 实时荧光定量PCR
分类号:
R735.7；R730.43
DOI:
10.3969/j.issn.1671-7414.2022.02.007
文献标志码:
A
摘要:
目的　探讨血清miRNA-574-3p，甲胎蛋白（alpha-fetoprotein, AFP、胰岛素样生长因子-2（insulin-like growth factor 2, IGF-2）联合诊断早期肝癌的价值。方法　选取2019 年4 月～ 2020 年11 月南通大学附属医院确诊的85 例早期肝癌患者和90 例健康体检者为研究对象，实时荧光定量逆转录聚合酶链反应（real-time fluorescent quantitative reverse transcription polymerase chain reaction，RT-PCR）测定血清中miRNA-574-3p 水平，化学发光法检测血清AFP 浓度，ELISA 法检测IGF-2 浓度，分析三者对早期肝癌的诊断价值。结果　早期肝癌组miRNA-574-3p，AFP 和IGF-2 分别为1.40±0.28 RQ ，94.13±25.05 ng/ml 和432.50±104.01 ng/ml，显著高于健康对照组（0.55±0.10 RQ ，10.05±3.34ng/ml和189.40±52.36ng/ml），差异有统计学意义 (t =5.368，12.401，18.514，均P <0.05)。miRNA-574-3p，AFP 和IGF-2诊断早期肝癌的曲线下面积分别为 0.801，0.787 和0.762，其中miRNA-574-3p 曲线下面积最大。AFP，IGF-2 分别联合miRNA-574-3p 诊断早期肝癌的曲线下面积为0.870，0.853 ，三者联合诊断价值最高，曲线下面积为0.917。结论　相比于AFP 和IGF-2，miRNA-574-3p 对早期肝癌诊断价值更高，临床上可通过 miRNA-574-3p 联合AFP，IGF-2 共同诊断以提高诊断效能。
Abstract:
Objective　To explore the diagnostic value of combined detection of serum miRNA-574-3p, alpha fetoprotein AFP (AFP) and insulin-like growth factor 2 IGF-2 (IGF-2) in the diagnosis of early liver cancer. Methods　Selected 85 patients with early liver cancer diagnosed in Affiliated Hospital of Nantong University from April 2019 to November 2020, and 90 healthy physical examination subjects were selected as the research object. Real-time fluorescent quantitative reverse transcription polymerase chain reaction (RT-PCR) detects the level of miRNA-574-3p in the serum, chemiluminescence method detects serum concentration, ELISA method detects concentration, and analyze the diagnostic value of the three for early liver cancer. Results　MiRNA-574-3p, AFP and IGF-2 in early hepatocellular carcinoma group were 1.40±0.28RQ, 94.13±25.05 ng/ml, 432.50±104.01ng/ml, respectively, significantly higher than those in healthy control group (0.55±0.10 RQ, 10.05±3.34 ng/ml, 189.40±52.36 ng/ml), the differences were statistically significant (t =5.368, 12.401, 18.514, all P <0.05).The area under the curve of miRNA-574-3p, AFP and IGF-2 in the diagnosis of early liver cancer were 0.801, 0.787 and 0.762, respectively, and the area under the curve of miRNA-574-3p was the largest. The area under the curve of AFP and IGF-2 combined with miRNA- 574-3p in the diagnosis of early liver cancer was 0.870 and 0.853 respectively. The combined diagnosis value of the three is the highest, and the area under the curve was 0.917. Conclusion　Compared with the common tumor markers AFP and IGF-2, miRNA-574-3p is more valuable in the diagnosis of early liver cancer. Clinically, miRNA-574-3p combined with AFP and IGF-2 can be used for joint diagnosis to improve the diagnostic efficiency.

参考文献/References:

[1] KIM J, KO M E, NELSON R A, et al. Increasing age and survival after orthotopic liver transplantation for patients with hepatocellular cancer[J]. Journal of the American College of Surgeons, 2014, 218(3): 431-438.
[2] 胡仁智, 赵世巧, 申波, 等. 血清甲胎蛋白及其异质 体和异常凝血酶原对原发性肝癌的诊断价值[J]. 中华肝脏病杂志, 2019,27(8):634 -637. HU Renzhi, ZHAO Shiqiao, SHEN Bo, et al. Diagnostic value of serum alpha-fetoprotein, alphafetoprotein variant and abnormal prothrombin in primary hepatocellular carcinoma [J]. Chinese Journal of Hepatology, 2019,27(8):634 -637.
[3] MARTINEZ-QUETGLAS I, PINYOL R, DAUCH D, et al. IGF2 is up-regulated by epigenetic mechanisms in hepatocellular carcinomas and is an actionable oncogene product in experimental models[J]． Gastroenterology, 2016 , 151(6):1192-1205.
[4] ZHANG Haifeng, WANG Yicheng, HAN Yidi. MicroRNA-34a inhibits liver cancer cell growth by reprogramming glucose metabolism[J]．Mol Med Rep, 2018 , 17(3):4483-4489.
[5] WANG Jing, LIANG Huimin, GE Haize, et al.MicroRNA-363-3p inhibits hepatocarcinogenesis by targeting HMGA2 and is associated with liver cancer stage[J]. Mol Med Rep, 2019, 19(2):935-942.
[6] 中华人民共和国卫生和计划生育委员会医政医管 局. 原发性肝癌诊疗规范(2017 年版)[J]. 中华肝脏 病杂志, 2017, 25(12):886-895. Bureau of Medical Administration, National Health and Family Planning Comission of the People’s Republic of China. Guideline and Consensus Diagnosis, management, and treatment of hepatocellular carcinoma (V2017) [J]. Chinese Journal of Hepatology, 2017, 25(12):886-895.
[7] SHEHAB-ELDEEN S, NADA A, ABOU-ELELA D, et al. Diagnostic performance of microRNA-122 and microRNA-224 in hepatitis C virus-induced hepatocellular carcinoma (HCC) [J]. Asian Pac J Cancer Prev, 2019, 20(8):2515-2522.
[8] TAI Bojun, YAO Min, ZHENG Wenjie ,et al. Alteration of oncogenic IGF-II gene methylation status associates with hepatocyte malignant transformation[J]. Hepatobiliary & Pancreatic Diseases International, 2019 , 18(2):158-163.
[9] 张筱东, 谢星星, 李佳, 等．血清外泌体miR-221 和 miR-378 水平检测在胃癌诊断中的应用研究[J]. 现 代检验医学杂志, 2020,35(6):52-55. ZHANG Xiaodong, XIE Xingxing, LI Jia, et al. Application study of serum exosome miR-221 and miR-378 detection in the diagnosis of gastric cancer[J].Journal of Modern Laboratory Medicine, 2020,35(6):52-55.
[10] ZHANG Xu, XU Xueying, GE Guohong, et al. miR- 498 inhibits the growth and metastasis of liver cancer by targeting ZEB2[J]. Oncology Reports, 2019, 41(3): 1638-1648.
[11] ZHANG Haifeng, WANG Yicheng, HAN Yidi. MicroRNA-34a inhibits liver cancer cell growth by reprogramming glucose metabolism[J]. Molecular Medicine Reports, 2018, 17(3): 4483-4489.
[12] MIZUGUCHI Y, MISHIMA T, YOKOMURO S, et al. Sequencing and bioinformatics-based analyses of the microRNA transcriptome in hepatitis B-related hepatocellular carcinoma[J]. PLoS One, 2011, 6(1):e15304.
[13] GUI Junhao, TIAN Yaping, WEN Xinyu, et al. Serum microRNA characterization identifies miR-885-5p as a potential marker for detecting liver pathologies[J]. Clinical Science (London, England : 1979), 2011, 120(5): 183-193.
[14] ZHA Zhongming, JIA Fuxin, HU Pingan, et al. MicroRNA-574-3p inhibits the malignant behavior of liver cancer cells by targeting ADAM28[J]. Oncology Letters, 2020, 20(3): 3015-3023.

备注/Memo

备注/Memo:
基金项目：国家自然科学基金面上项目（81271920)。
作者简介：卢美红（1975-），女，硕士，副主任技师，主要研究方向：临床免疫学检验，E-mail：alu522@126.com。
通讯作者：鞠少卿，男，主任技师，博士生导师，E-mail：jsq814@hotmail.com。
更新日期/Last Update: 1900-01-01